BI-4142
oral HER2 exon 20 mutants selective inhibitor tumor regression in the HER2YVMA xenograft model from 12k compounds in-house library screening and opt Nat. Cancer, July 26, 2022 Boehringer Ingelheim RCV, Vienna, AT
Molecules of the Month - July 2022